• Mashup Score: 2

    The risk of early recurrence in medically treated patients with intracranial atherosclerotic stenosis (ICAS) may differ in clinical trials versus real-world settings. Delayed enrollment may contribute to lower event rates in ICAS trials. We aim to determine the 30-day recurrence risk in a real-world setting of symptomatic ICAS.

    Tweet Tweets with this article
    • In patients with symptomatic #ICAD, the real-world recurrent #stroke is ~20% & >>>> than that seen in clinical trials (~4%) even in subgroups receiving the same pharmacological treatment strategies. Read our most recent on this! https://t.co/wFd7Xtdido @EricGoldsteinMD @ShuLiqi

  • Mashup Score: 2

    Intracranial stenosis (ICAS) is a common cause of stroke worldwide and patients with symptomatic ICAS exhibit a high rate of recurrence, particularly in the early period after the initial event. In this study, we aimed to study the association between borderzone infarct and recurrent ischemic stroke in patients hospitalized with symptomatic ICAS.

    Tweet Tweets with this article
    • Borderzone infarcts imply impaired blood flow and was associated with increased early recurrence in ICAD in this study. Would the high risk of early recurrence in ICAD be reduced by targeting high risk patients who mechanistically benefit from reperfusion? https://t.co/cEpleEi0Hp

  • Mashup Score: 6

    The coronavirus disease-2019 (COVID-19) pandemic caused unprecedented demand and burden on emergency health care services in New York City. We aim to describe our experience providing acute stroke care at a comprehensive stroke center (CSC) and the impact of the pandemic on the quality of care for patients presenting with acute ischemic stroke (AIS).

    Tweet Tweets with this article
    • Despite unprecedented demands on emergency healthcare services, early multidisciplinary efforts to adapt the acute stroke treatment process resulted in keeping the stroke quality time metrics close to pre-pandemic levels. @shashank_agarMD @eytanraz https://t.co/yoHpaxjgVF